ISTA Pharmaceuticals Reports Results From The First Of Two Trials In The REMURA(TM) Phase 3 Clinical Program For Dry Eye Disease
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced top-line results from the first of its two Phase 3 studies to evaluate the short-term safety and efficacy of two concentrations of REMURA(TM) (bromfenac ophthalmic solution for dry eye) in alleviating the signs and symptoms of dry eye disease. The company's Phase 3 safety and efficacy program, which consists of two studies known as EAST and WEST, is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA). Today's top-line results are from the WEST (Read more...)